ReviewHaematologica2023
How we manage cardiovascular disease in patients with hemophilia.
Review in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Ageing with Haemophilia: Comorbidities in Focus.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Hemophilia in the Era of Advanced Therapies: Structural Monitoring, the Role of Musculoskeletal Ultrasound, and a Proposed Multidisciplinary Care Model-A Structured Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.International journal of molecular sciences · 2026Review
- Case Report: Successful concomitant surgical interventions for dilated ascending aorta and aortic valve insufficiency in a severe haemophilia A case.Frontiers in medicine · 2026Article
- Percutaneous Left Atrial Appendage Closure: Current Evidence and Procedural Insights.Reviews in cardiovascular medicine · 2025Review
- In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry.International journal of hematology · 2025Article
- Myocardial Mechanics and Valvular and Vascular Abnormalities in Hemophilia.Reviews in cardiovascular medicine · 2025Review
- Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Is it safe to perform coronary artery bypass grafting surgery in patients with hemophilia? A case series of four patients.Turk gogus kalp damar cerrahisi dergisi · 2025Article
- Perioperative management of hemophilia A during coronary artery bypass grafting with patent foramen ovale repair.Journal of surgical case reports · 2024Article
- Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk.International journal of molecular sciences · 2024Review
- Modern Treatment of Valvulopathies in Patients with Congenital Hemophilia.Life (Basel, Switzerland) · 2024Review
- Hemophilia patients: are they naturally anticoagulated?Internal and emergency medicine · 2023Article
- Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance.HemaSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the striking advances in hemophilia care that have materialized particularly in the last two decades, an increasing number of persons with hemophilia (PWH) have achieved a quality of life and life expectancy very close to that of unaffected individuals. With aging, a growing number of PWH develop age-related co-morbidities, including cancer and cardiovascular disease. The latter (particularly coronary artery disease and atrial fibrillation) represent a new challenge for the hemophilia treatment centers because their management implies a delicate balance between the thrombotic risk and bleeding tendency, that is further enhanced by the concomitant use of antithrombotic agents. Because evidence from clinical trials is lacking, the management of PWH with cardiovascular diseases is mostly based on expert opinions, personal experiences, and the adaptation of the evidence stemming from studies on people without hemophilia. In this article, we focus on how to manage coronary artery disease and atrial fibrillation in patients with hemophilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.